Crossmark

Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center

Published Online: 2024-04-15

Published Print: 2024-10

Authors

van Pesch, Vincent https://orcid.org/0000-0003-2885-9004
Hanganu, Andreea-Raluca

Sankari, Souraya El https://orcid.org/0000-0001-5082-1243
License Information

Text and Data Mining valid from 2024-04-15

Version of Record valid from 2024-04-15
More Information

Article History

Received: 1 November 2023

Accepted: 23 March 2024

First Online: 15 April 2024

Declarations

:

: Prof. van Pesch received travel grants from Merck Healthcare KGaA (Darmstadt, Germany), Biogen, Sanofi, Bristol Meyer Squibb, Almirall and Roche. His institution has received research grants and consultancy fees from Roche, Biogen, Sanofi, Merck Healthcare KGaA (Darmstadt, Germany), Bristol Meyer Squibb, Janssen, Almirall, Novartis Pharma, and Alexion. Prof. El Sankari and Dr. Florea have no relevant financial or non-financial interests to disclose.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Document is current